Can azithromycin be used as treatment?

Can Azithromycin Be Used as Treatment?

Yes, azithromycin can be used as treatment for specific bacterial infections where it is indicated, but it should not be used indiscriminately—appropriate culture and susceptibility testing should guide therapy, and it must only be prescribed for proven or strongly suspected bacterial infections to prevent antimicrobial resistance. 1

FDA-Approved Indications

Azithromycin is FDA-approved for treatment of the following conditions 1:

In Adults:

• Respiratory infections: Community-acquired pneumonia (CAP), acute bacterial exacerbations of COPD, acute bacterial sinusitis
• Skin infections: Uncomplicated skin and skin structure infections
• Sexually transmitted infections: Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae, genital ulcer disease (chancroid)
• Pharyngitis/tonsillitis: As alternative therapy when first-line agents cannot be used

In Pediatric Patients:

• Acute otitis media
• Community-acquired pneumonia
• Pharyngitis/tonsillitis (as alternative therapy)

Key Prescribing Principles

Culture and susceptibility testing should be performed before initiating azithromycin therapy 1. While treatment may begin empirically, antimicrobial therapy must be adjusted once results become available. This is critical because:

• Some strains of Streptococcus pyogenes are resistant to azithromycin and require susceptibility testing 1
• Azithromycin should not be relied upon to treat syphilis 1
• Local epidemiology and resistance patterns should inform empiric selection 1

Specific Clinical Contexts

Pertussis (Whooping Cough)

Azithromycin is a preferred first-line agent for pertussis treatment and prophylaxis 2:

• Infants <1 month: Azithromycin is the PREFERRED macrolide (10 mg/kg/day for 5 days) due to lower risk of infantile hypertrophic pyloric stenosis (IHPS) compared to erythromycin 2
• Infants 1-5 months: 10 mg/kg/day for 5 days 2
• Children ≥6 months: 10 mg/kg (max 500 mg) day 1, then 5 mg/kg/day (max 250 mg) days 2-5 2
• Adults: 500 mg day 1, then 250 mg/day days 2-5 2

Azithromycin offers better tolerability, fewer side effects, and easier adherence compared to erythromycin (once daily vs. four times daily) 2.

Nontuberculous Mycobacterial (NTM) Infections

A macrolide (clarithromycin or azithromycin) is the cornerstone of therapy for disseminated MAC and NTM pulmonary disease 3, 4:

• For disseminated MAC in AIDS patients: Clarithromycin 1000 mg/day or azithromycin 500 mg daily, always combined with ethambutol 3
• Clarithromycin clears bacteremia more rapidly than azithromycin 3
• Monotherapy is contraindicated due to rapid resistance development 3
• For M. abscessus: Azithromycin or clarithromycin is included in multi-drug regimens, with activity dependent on macrolide resistance patterns 4

Community-Acquired Pneumonia

Azithromycin is appropriate for CAP in patients suitable for oral therapy 1. However:

• Do NOT use in patients with moderate-to-severe illness, cystic fibrosis, nosocomial infections, known/suspected bacteremia, or those requiring hospitalization 1
• Recent evidence suggests azithromycin is often prescribed inappropriately without meeting severity criteria 5

Tularemia

Azithromycin has been added as an alternative option for post-exposure prophylaxis and as a third-tier treatment option for tularemia, though first-line agents are preferred 6.

Important Safety Considerations

Contraindications and Precautions 1:

• Hepatic impairment: Use with caution as azithromycin is primarily eliminated via the liver
• Renal insufficiency: Exercise caution in patients with GFR <10 mL/min
• Myasthenia gravis: Can exacerbate symptoms or cause new-onset myasthenic syndrome
• QTc prolongation: Risk of cardiac arrhythmias, particularly when combined with other QT-prolonging drugs

Drug Interactions 1:

• Warfarin: May potentiate anticoagulant effects; monitor prothrombin time closely
• Antacids: Do not take aluminum- or magnesium-containing antacids simultaneously (reduces absorption)
• Unlike erythromycin and clarithromycin, azithromycin does NOT inhibit cytochrome P450 enzymes, resulting in fewer drug interactions 2

Common Adverse Effects 2:

• Gastrointestinal: Abdominal discomfort, diarrhea, nausea, vomiting
• Headache and dizziness
• Generally better tolerated than erythromycin

When NOT to Use Azithromycin

Syphilis

Azithromycin should NOT be used to treat syphilis in the United States 7, 1. Despite some international data showing efficacy with single 2-g doses, macrolide resistance mutations in Treponema pallidum are highly prevalent in the U.S., leading to treatment failures 7.

COVID-19

Do NOT use azithromycin (with or without hydroxychloroquine) for COVID-19 treatment or prophylaxis outside of clinical trials 8. There is:

• No available evidence for prophylaxis
• Insufficient evidence about benefits and harms for treatment
• Serious safety concerns regarding QTc prolongation when combined with hydroxychloroquine

Gonorrhea Treatment Failures

While azithromycin 2 g orally combined with gentamicin 240 mg IM may be effective for extragenital azithromycin-susceptible N. gonorrhoeae infections, azithromycin resistance varies substantially by region (4-66%) 9. This limits its utility as an alternative treatment.

Antimicrobial Stewardship

Prescribing azithromycin without proven or strongly suspected bacterial infection increases the risk of drug-resistant bacteria 1. Key principles:

• Use only when culture/susceptibility data or local epidemiology support its use
• Complete the full course of therapy—skipping doses or incomplete treatment promotes resistance 1
• Consider that azithromycin's long half-life (68 hours) creates prolonged subinhibitory concentrations that may select for resistant organisms 10

Dosing Considerations

The typical adult dosing is 500 mg on day 1, followed by 250 mg daily on days 2-5 2. However, single-dose regimens (e.g., 30 mg/kg for pediatric acute otitis media) have demonstrated comparable efficacy with potential for enhanced adherence 11. Three-day regimens (500 mg once daily) have shown equivalent efficacy to longer courses of comparator antibiotics for lower respiratory tract infections 12.